Biocon Biologics Garners $75m ADQ Investment
Biocon Subsidiary Now Valued At More Than $4bn After Private Equity Deal
Biocon has secured the latest in a series of investments in its Biocon Biologics subsidiary, from Abu Dhabi based ADQ. The transaction, worth around $75m, values the biosimilars unit at $4.17bn.
You may also be interested in...
Biocon Biologics And Serum Institute Join Forces
Serum to hold 15% in Biocon arm Biocon Biologics as part of a broad alliance that expects to leverage the partners' strengths and resources in vaccines and biologics. Pursuing opportunities based on the hot mRNA technology platform appears firmly on the table.
Biocon Biologics Refreshes Management
Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.